NDV-01 (sustained-release gemcitabine-docetaxel)

DRUG3 trials

Sponsors

Relmada Therapeutics, Inc.

Conditions

Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urologic CancerUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent

Phase 3

A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

WithdrawnNCT07313891

Relmada Therapeutics, Inc.Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urologic Cancer +1

Start: 2026-05-01End: 2029-11-01Updated: 2026-03-17

A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

WithdrawnNCT07342517

Relmada Therapeutics, Inc.Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urologic Cancer +2

Start: 2026-06-30End: 2028-06-30Updated: 2026-03-17

A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Not yet recruitingNCT07464145

Relmada Therapeutics, Inc.Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urologic Cancer +2

Start: 2027-02-01End: 2032-12-01Target: 393Updated: 2026-09-02